RxDoctor Payments DataLook up a doctor →

David Glaser, MD

Retina Specialist · Florissant, MONPI 1891807137

Payments from drug & device makers

$108,760in general payments, 2019–2025

Across 285 payments — averaging $381.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$89K
  • US Retina LLC$9K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$1K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Genentech USA, Inc.$1K
  • AbbVie$1K
  • plus $6K from 20 others

What the payments were for

  • Food & beverage$10,47853%
  • Gifts$190%
  • Ownership interest$3,64719%
  • Other$5,54328%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$108,760 in reported general payments places this provider in the 80th percentile of 45 retina specialist providers in Missouri.

See all retina specialist providers in Missouri

Medicare billing

Part B allowed, 2024
$1,651,770
Medicare patients
576
Services billed
11,250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProlensaBromfenac Sodium23$7,931
LumiganBimatoprost18$7,816
Bromfenac Sodium20$5,188
Tobramycin-DexamethasoneTobramycin/Dexamethasone79$3,467
Prednisolone Acetate34$1,067
Ketorolac Tromethamine43$810
Acetazolamide13$659
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol11$520
Latanoprost44$388
Timolol Maleate20$165
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat17$147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$1,218$7,93123 claims
AbbVieLumigan$1,049$7,81618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 45 retina specialist providers in Missouri.

Other retina specialist in Florissant

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →